When was Amass founded?

Amass was founded in 2022 and raised its 1st funding round 3 years after it was founded.

Where is Amass located?

Amass is headquartered in Frederiksberg, Denmark. It is registered at 7, Ewaldsgade, København N, 2200.

How many employees does Amass have?

As of Jun 30, 2026, the latest employee count at Amass is 7.

Is Amass a funded company?

Amass is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 22, 2025.

When was the latest funding round of Amass?

Amass' latest funding was a $***** Seed round on Aug 22, 2025, with participation from 2 investors.

Where does Amass rank among its competitors?

Amass ranks 353rd amongst 1976 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Amass?

Amass' top competitors include Antheia, Transcenta and Akeso. Among them, Antheia secured the most recent funding round in January, 2026.

Amass - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Provider of an AI-powered platform for scientific knowledge integration and analysis. The platform integrates scientific data from various sources, including patents, papers, regulatory filings, and internal documents, into a structured knowledge graph. It offers tools for literature intelligence, competitive and market intelligence, and AI-powered scientific Q&A. The platform is designed for use across various roles, from researchers to business strategists, to facilitate scientific discovery and decision-making.

Website: www.amass.tech/
Registered Address: 7, Ewaldsgade, København N, 2200

Key Metrics

Founded Year

2022

Location

Frederiksberg, Denmark

Stage

Seed

Total Funding

$1.63M in 1 round

Latest Funding Round

Seed, Aug 22, 2025, $*****

Investors

Giant Ventures & 2 more

Ranked

353^rd among 1976 active competitors

Employee Count

7 as on Jun 30, 2026

Similar Companies

OpenEvidence & 5024 more

View Amass' full profile

Amass is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
amass technologies Aps CIN: 43657992 , Denmark, Active	Nov 21, 2022	-	-

Amass has raised a total funding of $1.63M over 1 round. Its latest funding round was a Seed round on Aug 22, 2025 for $*****. 2 investors participated in its latest round. Amass has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Amass:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 22, 2025	3284353	Seed	8256202	5656015	4799707	4986617

Access funding benchmarks and valuations. Sign up today!

View details of Amass's funding rounds and investors

Amass' employee count trend

Amass has 7 employees as of Jun 26. Here is Amass's employee count trend over the years:

Uncover Amass' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amass include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Amass, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, Polaris Partners & 16 others	62/100
8th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
9th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	61/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	F-Prime Capital, Perceptive Advisors & 22 others	61/100
353rd	Amass 2022, Frederiksberg (Denmark), Seed	Provider of an AI-powered platform for scientific knowledge integration and analysis	$1.63M	Giant Ventures, Kost & 1 others	37/100